Bright Minds Biosciences (DRUG) Total Liabilities (2020 - 2026)

Bright Minds Biosciences' Total Liabilities history runs 7 years deep, the most recent figure standing at $2.8 million for Q1 2026.

• Quarterly Total Liabilities rose 451.76% year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 million (up 451.76% YoY) and the FY2025 annual result came in at $1.7 million, up 314.57% from the prior year.
• Total Liabilities was $2.8 million for Q1 2026 at Bright Minds Biosciences, up from $1.1 million in the prior quarter.
• Across five years, Total Liabilities topped out at $2.8 million in Q1 2026 and bottomed at $130602.2 in Q2 2024.
• A 5-year average of $770744.7 and a median of $547032.6 in 2023 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2023 — Total Liabilities sank 82.31% — and 2026, when it soared 451.76%.
• Bright Minds Biosciences' Total Liabilities stood at $429247.3 in 2022, then surged by 46.17% to $627410.9 in 2023, then sank by 34.78% to $409172.2 in 2024, then surged by 180.28% to $1.1 million in 2025, then jumped by 143.7% to $2.8 million in 2026.
• Business Quant data shows DRUG's Total Liabilities at $2.8 million in Q1 2026, $1.1 million in Q4 2025, and $1.7 million in Q3 2025.